Atrial Antitachycardia Pacing and Managed Ventricular Pacing Reduce the Endpoint Composed by Death, Cardiovascular Hospitalizations, and Permanent Atrial Fibrillation - Minerva Randomized Study
The goal of the trial was to evaluate atrial anti-tachycardia pacing (DDDRP) and managed ventricular pacing (MVP) among patients with bradycardia and previous atrial tachyarrhythmia.
DDDRP and MVP will reduce atrial fibrillation occurrence and minimize right ventricular detrimental effects.
- Patients with bradycardia and prior atrial tachyarrhythmia
Number of enrollees: 1,166 patients
Mean patient age: 74 years
Percentage female: 50%
- Death, cardiovascular hospitalization, or permanent atrial fibrillation
Patients with bradycardia and previous atrial tachyarrhythmia who recently underwent permanent pacemaker placement were randomized to DDDR (n = 385), vs. DDDRP + MVP (n = 383), vs. MVP (n = 398).
Overall, 1,166 patients were randomized. The mean age was 74 years, and 50% were women.
The primary outcome occurred in 26.5% of the DDDR control group, 19.8% of the DDDRP + MVP group (p = 0.04 vs. control), and 21.4% of the MVP group (p = 0.12 vs. control).
DDDRP + MVP was associated with a reduction in permanent atrial fibrillation (hazard ratio = 0.39, p = 0.004).
Among patients with bradycardia and atrial tachyarrhythmia, the pacer mode DDDRP + MVP was superior at reducing composite cardiovascular outcomes compared with standard dual-chamber pacing. This was mainly due to prevention of permanent atrial fibrillation.
Presented by Dr. Giuseppe Boriani at the American Heart Association Scientific Sessions, Dallas, TX, November 18, 2013.
Keywords: Pacemaker, Artificial, Bradycardia, Heart Ventricles, Tachycardia
< Back to Listings